Galena Biopharma (GALE -18.7%) discloses the details of its unspecified secondary offering announced late yesterday, saying it sold 15.2M units for gross proceeds of about $24.3M. The units - consisting of one share of stock and a warrant - priced at $1.60 each. The warrants entitle holders to purchase half a share at an exercise price of $1.90. The company intends to use the proceeds for clinical trials of its breast cancer treatment NeuVax and a trial of its Folate Binding Protein-E39. The company has a current float of around 67.6M shares.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at CNBC.com (May 21, 2014)
at CNBC.com (Apr 8, 2014)
at CNBC.com (Mar 17, 2014)
at MarketWatch.com (Mar 17, 2014)
at CNBC.com (Jan 16, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs